# ScoreItem: HCO3 (Bicarbonato)

**ID:** `c77cedd3-2800-78ea-9874-171a333c7c9e`
**FullName:** HCO3 (Bicarbonato) (Exames - Laboratoriais)
**Unit:** mEq/L

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 9 artigos
- Avg Similarity: 0.596

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-78ea-9874-171a333c7c9e`.**

```json
{
  "score_item_id": "c77cedd3-2800-78ea-9874-171a333c7c9e",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** HCO3 (Bicarbonato) (Exames - Laboratoriais)
**Unidade:** mEq/L

**30 chunks de 9 artigos (avg similarity: 0.596)**

### Chunk 1/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.649

1‚ÄìA3).Theyaxisrepresentsthemeta-analyzedabsolutedifferencefromthemeanadjustedvalueataneGFRof80ml/minper1.73m2andalbuminexcretion<30mg/g(<3mg/mmol).ReproducedfromAmericanJournalofKidneyDiseases,volume73,issue2,InkerLA,GramsME,LeveyAS,etal.RelationshipofestimatedGFRand
albuminuriatoconcurrentlaboratoryabnormalities:anindividual
participantdatameta-analysisinaGlobalConsortium,pages206‚Äì217,Copyright¬™2018,withpermissionfromtheNationalKidneyFoundation,Inc.541
Table23|Variationoflaboratoryvaluesinalargepopulationdatabaseabyagegroup,sex,andeGFR;bicarbonate,mmol/l,mean(SD),andn[3,990,898Measure,mean(SD)Age(yr)SexGFRcategory(ml/minper1.73m2)105D90‚Äì10475‚Äì8960‚Äì7445‚Äì5930‚Äì4415‚Äì290‚Äì14Serumbicarbonate$65Female27.4(4.1)27.1(2.9)26.9(2.9)26.8(2.9)26.5(3.1)25.9(3.5)24.8(4.0)24.0(4.8)Male27.1(3.9)26.6(2.9)26.7(2.9)26.5(2.9)26.1(3.1)25.3(3.8)24.1(4.0)24.2(4.8)<65Female25.2(2.8)26.1(2.8)26.3(2.8)26.4(2.9)26.2(3.2)25.1(3.6)23.6(4.2)24.0(5.0)Male26.4(2.8)26.5(3.0)26.6(2.7)26.5(2.9)25.9(3.2)

---

### Chunk 2/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.649

9,540Thecausalityofsuchassociationsremainstobedemonstrated.Denitionandprevalence.SerumbicarbonateconcentrationbeginstofallprogressivelyonceeGFRfallsbelow60ml/minper1.73m2withreductionsmostevidentinCKDstagesG4‚ÄìG5(Figure28,541Table23).Theadjustedadultprevalenceofserumbicarbonate<22mmol/lwas7.7%and6.7%inthosewithandwithoutdiabetesatstageG3,A1,respectively,increasingto38.3%and35.9%byCKDstageG5,A3.PracticePoint3.10.1:InpeoplewithCKD,consideruseofpharmacologicaltreatmentwithorwithoutdietaryinter-
ventiontopreventdevelopmentofacidosiswithpotential
clinicalimplications(e.g.,serumbicarbonate<18mmol/linadults).PracticePoint3.10.2:Monitortreatmentformetabolicacidosistoensureitdoesnotresultinserumbicarbonate
concentrationsexceedingtheupperlimitofnormaland
doesnotadverselyaffectBPcontrol,serumpotassium,or
uidstatus.TheWorkGrouphasnotprovidedagradedrecommen-dationforthetreatmentofacidosisduetoalackoflarge-scale
RCTssupportingitsuse.In2012,a2Brecommendationwasjustiedbecausealkalisupplementationm

---

### Chunk 3/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.638

ostudy
medicationonkidneyoutcomes.Ofthe15trials(2445
participants,medianfollow-up12months),11were
publishedsince2012.Thetotalityoftheevidenceremainslimitedbyalownumberofoutcomes,andmeta-analysisrestrictedtotheplacebo-controlledtrialsdoesnotconrmanyimportantmodifyingeffectoforalsodiumbicarbonate
versusplaceboonriskofkidneyfailure(HR:0.81;95%CI:
0.54‚Äì1.22).542Thelargestplacebo-controlledtrialoforalsodiumbicarbonatewasconductedbytheClinicaland
cost-effectivenessoforalsodiumbicarbonatetherapyfor
‚Äì5‚Äì4‚Äì3‚Äì2‚Äì11015304560759010512
0
eGFR, ml/min/1.73 m2Serum bicarbonate, mmol/lA1A2A3
Figure28|Associationbetweenestimatedglomerularltrationrate(eGFR)withserumbicarbonateconcentrationingeneralpopulationandhigh-riskcohortsfromtheChronicKidney
DiseasePrognosisConsortium,bylevelofalbuminuria(A1‚ÄìA3).Theyaxisrepresentsthemeta-analyzedabsolutedifferencefromthemeanadjustedvalueataneGFRof80ml/minper1.73m2andalbuminexcretion<30mg/g(<3mg/mmol).ReproducedfromAmericanJournalofKidneyDiseases,volum

---

### Chunk 4/30
**Article:** Bioqu√≠mica Metab√≥lica nos Exerc√≠cios - Parte III (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.635

exerc√≠cio e recupera√ß√£o; manter R basal 0,98‚Äì1,02 e prevenir acidose cr√¥nica e sequestro √≥sseo.
- [ ] 18. Programar reavalia√ß√£o de exames e desempenho em 1‚Äì2 meses, at√© 2025-12-20 ou 2026-01-20; ajustar o plano conforme resultados.
- [ ] 19. Educar pacientes sobre metas bioqu√≠micas, uso correto de aer√≥bico em jejum e reavalia√ß√µes frequentes, refor√ßando ades√£o por metas claras e feedback imediato.

---

## Teaching Note

Data e Hora: 2025-11-20 19:22:20
Local: [Inserir Local]
Aula: Medicina Funcional Integrativa - Bioqu√≠mica do Metabolismo nas Atividades F√≠sicas
## Vis√£o Geral
A aula abordou a bioqu√≠mica do metabolismo em atividades f√≠sicas, focando em como a intensidade do exerc√≠cio influencia as respostas hormonais e metab√≥licas.

---

### Chunk 5/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.634

ies:anindividual
participantdatameta-analysisinaGlobalConsortium.AmJKidneyDis.2019;73:206‚Äì217.542.HultinS,HoodC,CampbellKL,etal.Asystematicreviewandmeta-
analysisoneffectsofbicarbonatetherapyonkidneyoutcomes.KidneyIntRep.2021;6:695‚Äì705.543.BiCarbStudyGroup.Clinicalandcost-effectivenessoforalsodium
bicarbonatetherapyforolderpatientswithchronickidneydisease
andlow-gradeacidosis(BiCARB):apragmaticrandomised,double-blind,placebo-controlledtrial.BMCMed.2020;18:91.544.WessonDE,MathurV,TangriN,etal.Long-termsafetyandefcacyofveverimerinpatientswithmetabolicacidosisinchronickidney
disease:amulticentre,randomised,blinded,placebo-controlled,40-weekextension.Lancet.2019;394:396‚Äì406.545.MathurVS,BushinskyDA,InkerL,etal.DesignandpopulationoftheVALOR-CKDstudy:amulticenter,randomized,double-blindplacebo-controlledtrialevaluatingtheefcacyandsafetyofveverimerinslowingprogressionofchronickidneydiseaseinpatientswithmetabolicacidosis.NephrolDialTransplant.2023;38:1448‚Äì1458.546.CarreroJJ,Gonzalez-

---

### Chunk 6/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.621

alysisinitsbicarbonateversusplaceboarms,respectively(HR:0.97;95%CI:0.64‚Äì1.49).Importantly,theBiCARBtrial,whichstudiedpeoplewithCKDG3‚ÄìG4aged$60yearsandsodiumbicarbonateconcentration<22mmol/l,alsofoundnoevidenceofbenetonnonkidneyoutcomestosupportoralsodiumbicarbonatesupplementation(theprimaryoutcomewasbasedontheShortPhysical
PerformanceBatteryat12months,andsecondaryoutcomes
includedgenericanddisease-specicQoLassessments,anthropometry,kidneyfunction,walkdistance,BP,and
boneandvascularhealthmarkers).Allocationtooral
sodiumbicarbonatewasassociatedwithhighercostsand
lowerEuropeanQualityofLife5Dimensions3Level
Version(EQ-5D-3L)assessedQoLover1year.543Licensednon-alkalioralinterventionsmaybeanalterna-tivetooralsodiumbicarbonatetotreatmetabolicacidosisbut
havenotbeenshowntohaveparticularadvantages.544,545Althoughplacebo-controlledtrialshavefoundnogood
evidencethatcorrectingsodiumbicarbonatelevelshas
importanteffectsonclinicaloutcomes,theWorkGroup
concludedthattheinterventionisclearlyeffec

---

### Chunk 7/30
**Article:** Dieta Cetog√™nica - Parte I (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.621

mg/dL pode ser tolerado quando h√° cetonas.
- Metas de GKI: corte <3 e ideal <1 para cetose profunda em terapia metab√≥lica; pH sangu√≠neo permanece ~7,4 na dieta normal/cetog√™nica, refutando ‚Äúsangue √°cido‚Äù.
**Achados em desempenho e casos aned√≥ticos indicam que a cetose tamb√©m √© compat√≠vel com alta performance, embora exigindo per√≠odos maiores de adapta√ß√£o.**
- Atletas de elite podem manter cetose ingerindo at√© ~100 g de carboidratos/dia; alguns atletas consomem 6‚Äì12 mil calorias/dia; necessidade hipot√©tica de carboidratos pode chegar a 800 g/dia fora da cetose, mas h√° flexibilidade com uso de corpos cet√¥nicos.
- Relato pessoal menciona aus√™ncia de crises de enxaqueca por cinco anos atribu√≠da ao estilo de vida/dieta cetog√™nica; cita atletas de alto desempenho com vit√≥rias no Tour de France usando low carb/cetog√™nica, refor√ßando aplicabilidade em elite.

---

### Chunk 8/30
**Article:** Bioqu√≠mica Metab√≥lica nos Exerc√≠cios - Parte III (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.618

de mitocondrial; falhas geram ‚Äúvai e volta‚Äù e ac√∫mulo de gordura.
- Acidose, imunidade e intestino: maior am√¥nia e tamponamento por glutamina reduzem substrato para imune/enter√≥citos; risco de leaky gut e imunossupress√£o.
### 11. √çndice R (bicarbonato/PCO2) e equil√≠brio √°cido-base
- Defini√ß√£o: R = SBC/HCO3- (SBC em PCO2 40 mmHg); normal ‚âà 1; ideal basal 0,98‚Äì1,02.
- Uso: avalia custo metab√≥lico em repouso, exerc√≠cio e recupera√ß√£o; acidose sustentada eleva risco de doen√ßa e custo fisiol√≥gico; baixo bicarbonato indica tamponamento √≥sseo e risco de perda de densidade.
- Cen√°rios de recupera√ß√£o:
  - pH normal + PCO2‚Üë + lactato‚Üë: recupera√ß√£o sist√™mica ok; continuar com aer√≥bico leve.
  - PCO2‚Üì + pH‚Üì + lactato‚Üë: sem recupera√ß√£o; prolongar descanso.
### 12. Suplementa√ß√£o
- Glutamina: tamp√£o de am√¥nia, suporte imune/intestinal e s√≠ntese de glutationa; √∫til em alta intensidade/acidose e fadiga com glutamina baixa.

---

### Chunk 9/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.615

ium,or
uidstatus.TheWorkGrouphasnotprovidedagradedrecommen-dationforthetreatmentofacidosisduetoalackoflarge-scale
RCTssupportingitsuse.In2012,a2Brecommendationwasjustiedbecausealkalisupplementationmaybeapromisinglow-cost,high-benetadjuncttreatmentforpeoplewithCKDandmaybeaccessibletoallpopulations.ThiswasbasedonanRCTthathadsuggestedpotentialkidneydiseaseprogression
andnutritionalbenetswithnoimportantincreaseinBPorheartfailurecomplications.1However,since2012,anumberoftrialstestingthehypothesisthatsodiumbicarbonate
therapywouldslowkidneydiseaseprogressionhavebeenreported,includingseveralemployingplacebocontrol.A2021systematicreviewidentied15trialswith$3monthsoffollow-upinpeoplewithCKD(eGFR<60ml/minper1.73m2and/orproteinuria)comparingtheeffectsoforalsodiumbicarbonateversusplaceboorversusnostudy
medicationonkidneyoutcomes.Ofthe15trials(2445
participants,medianfollow-up12months),11were
publishedsince2012.Thetotalityoftheevidenceremainslimitedbyalownumberofoutcomes,andmeta-analysisrestri

---

### Chunk 10/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.611

tages.544,545Althoughplacebo-controlledtrialshavefoundnogood
evidencethatcorrectingsodiumbicarbonatelevelshas
importanteffectsonclinicaloutcomes,theWorkGroup
concludedthattheinterventionisclearlyeffectiveat
increasingserumbicarbonateconcentrationandisa
suitabletreatmenttoavoidmoresevereacidosiswith
potentialforclinicalimplications.TheWorkGroupsuggests
thataserumbicarbonateof<18mmol/linadultsisdesirabletoavoid,butlargeRCTsarerequiredtodetermine
aprecisethresholdwherebythetreatmentoflowserum
bicarbonatelevelsleadstoimprovementsinclinical
outcome.Ascorrectionofbicarbonatetothenormalrange
hasnotbeendemonstratedtoreducetheriskofkidney
failure,lowerthresholdstoinitiatetherapythan18mmol/l
couldbeconsidered(seeResearchRecommendations).Dietaryapproaches.Dietarymodicationsthatlimittheconsumptionofacid-richfoodsand/orincreasetheintakeof
alkaline-richfoodsreducethenetendogenousacidproduction
andcanserveasanadditionalstrategytocontrolmetabolic
acidosisinpeoplewithCKD.546,547Suchdietsaregenerallylo

---

### Chunk 11/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.601

etablesorsodiumbicarbonate.ClinJAmSocNephrol.2013;8:371‚Äì381.550.GorayaN,SimoniJ,JoCH,etal.Treatmentofmetabolicacidosisin
patientswithstage3chronickidneydiseasewithfruitsand
vegetablesororalbicarbonatereducesurineangiotensinogenand
preservesglomerularltrationrate.KidneyInt.2014;86:1031‚Äì1038.551.NoceA,MarroneG,WilsonJonesG,etal.Nutritionalapproachesforthe
managementofmetabolicacidosisinchronickidneydisease.Nutrients.2021;13:2534.552.BrownDD,RoemJ,NgDK,etal.LowserumbicarbonateandCKD
progressioninchildren.ClinJAmSocNephrol.2020;15:755‚Äì765.553.BrownDD,CarrollM,NgDK,etal.Longitudinalassociationsbetween
lowserumbicarbonateandlineargrowthinchildrenwithCKD.

---

### Chunk 12/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.594

matedglomerularltrationrate(eGFR)andhemoglobinconcentrationfromgeneralpopulationandhigh-riskcohortsfromtheChronicKidneyDisease
PrognosisConsortium,bydiabetesstatus.Theyaxisrepresentsthemeta-analyzedabsolutedifferencefromthemeanadjustedvalue
ataneGFRof80ml/minper1.73m2andalbuminexcretion<30mg/g(<3mg/mmol).ReproducedfromAmericanJournalofKidneyDiseases,volume73,issue2,InkerLA,GramsME,LeveyAS,etal.Relationshipof
estimatedGFRandalbuminuriatoconcurrentlaboratoryabnormalities:
anindividualparticipantdatameta-analysisinaGlobalConsortium,
pages206‚Äì217,Copyright¬™2018,withpermissionfromtheNationalKidneyFoundation,Inc.541
www.kidney-international.orgchapter3KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314S229

extraskeletal(i.e.,vascular)calcicationrelatedtotheseabnormalitiesofmetabolism.IthasbeenrecommendedthatinpeoplewithCKDG3a‚ÄìG5,treatmentsofCKD-MBDshouldbebasedonserialassessmentsofphosphate,calcium,andPTHlevelsconsideredtogether.20Higherserumphosphateconcentrationsareassociatedwithmort

---

### Chunk 13/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.592

0.2:MonitortreatmentformetabolicacidosistoensureitdoesnotresultinserumbicarbonateconcentrationsexceedingtheupperlimitofnormalanddoesnotadverselyaffectBPcontrol,serumpotassium,oruidstatus.3.11HyperkalemiainCKD3.11.1AwarenessoffactorsimpactingonpotassiummeasurementPracticePoint3.11.1.1:Beawareofthevariabilityofpotassiumlaboratorymeasurementsaswellasfactorsandmech-anismsthatmayinuencepotassiummeasurementincludingdiurnalandseasonalvariation,plasmaversusserumsamples,andtheactionsofmedications.3.11.2Potassiumexchangeagents
PracticePoint3.11.2.1:Beawareoflocalavailabilityorformularyrestrictionswithregardtothepharmacologicman-agementofnonemergenthyperkalemia.3.11.3Timingtorecheckpotassiumafteridentifyingmoderateandseverehyperkalemiainadults[Norecommendationsandpracticepoints]
K+ ‚â§4.8 mmol/lK+ 4.9‚Äì5.5 mmol/lK+ >5.5 mmol/l‚Ä¢ Initiate nerenone  - 10 mg daily if eGFR 25‚Äì59 ml/min/1.73 m2  - 20 mg daily if eGFR ‚â•60 ml/min/1.73 m2‚Ä¢ Monitor K+ at 1 month after initiation and then every

---

### Chunk 14/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.588

rgS160KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314

3.11.4Managinghyperkalemia[Norecommendationsandpracticepoints]3.11.5DietaryconsiderationsPracticePoint3.11.5.1:ImplementanindividualizedapproachinpeoplewithCKDG3‚ÄìG5andemergenthyperkalemiathatincludesdietaryandpharmacologicinterventionsandtakesintoconsiderationassociatedcomor-biditiesandqualityoflife(QoL).Assessmentandeducationthrougharenaldietitianoranaccredited
nutritionproviderareadvised.PracticePoint3.11.5.2:Provideadvicetolimittheintakeoffoodsrichinbioavailablepotassium(e.g.,processedfoods)forpeoplewithCKDG3‚ÄìG5whohaveahistoryofhyperkalemiaorasapreventionstrategyduringdiseaseperiodsinwhichhyperkalemiariskmaybeaconcern.3.12Anemia
TheKDIGO2012ClinicalPracticeGuidelineforAnemiainChronicKidneyDiseasewillbeupdatedin2024.4373.13CKD-MineralBoneDisorder(CKD-MBD)
TheWorkGrouphighlightstheKDIGO2017ClinicalPracticeGuidelineUpdatefortheDiagnosis,Evaluation,Prevention,andTreatmentofChronicKidneyDisease‚ÄìMineralandBoneDisorder(CKD-MBD)

---

### Chunk 15/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.584

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 16/30
**Article:** Trato Gastrointestinal III ‚Äì est√¥mago ‚Äì hipocloridria (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.583

e tratar as causas subjacentes dos problemas de sa√∫de, em vez de apenas suprimir sintomas.
### 2. Diagn√≥stico e Estrat√©gias de Gest√£o da Hipocloridria
*   **Teste Caseiro com Bicarbonato de S√≥dio**
    *   **Procedimento:** Misturar meia colher de caf√© de bicarbonato de s√≥dio em √°gua e beber em jejum.
    *   **Interpreta√ß√£o:** Arrotar em menos de 2 minutos sugere poss√≠vel excesso de √°cido; entre 2-3 minutos √© normal; acima de 5 minutos (ou n√£o arrotar) sugere hipocloridria.
*   **Estrat√©gias Fundamentais de Estilo de Vida e Nutri√ß√£o**
    *   **1. Fase Cef√°lica e Mastiga√ß√£o:** Evitar telas e mastigar bem os alimentos at√© se tornarem l√≠quidos.
    *   **2. Gerenciamento do Estresse:** Evitar estresse durante as refei√ß√µes, pois as catecolaminas prejudicam a digest√£o.
    - **3. Cuidado com L√≠quidos:** Evitar excesso de l√≠quidos durante as refei√ß√µes. Se beber, preferir l√≠quidos acidificados (√°gua com lim√£o, vinagre de ma√ß√£).

---

### Chunk 17/30
**Article:** Trato Gastrointestinal II- est√¥mago ‚Äì hipercloridria e hipocloridria (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.581

bicarbonato pelo est√¥mago; compensa√ß√£o via remo√ß√£o de c√°lcio dos ossos para alcalinizar o sangue.
   - Maior √≠ndice de depress√£o: folato √© limitante para serotonina; triptofano-hidroxilase depende de folato; convers√£o de 5-HTP em serotonina depende de B6 ativa (PLP). Defici√™ncias elevam o risco.
   - Modifica√ß√£o do microbioma intestinal por putrefa√ß√£o proteica; gera√ß√£o de TMAO (√≥xido de trimetilamina) que aumenta MAO (monoamina oxidase), degradando serotonina, dopamina e noradrenalina, reduzindo a√ß√£o nas fendas sin√°pticas e contribuindo para depress√£o.
   - Associa√ß√£o com pneumonia por refluxo com carga bacteriana n√£o inativada.
   - Mais infec√ß√µes intestinais e menor imunidade por quimo pouco √°cido, comprometendo a prote√ß√£o da mucosa intestinal.
### 8. Medicina Baseada em Evid√™ncias (MBE) e Abordagem Integrativa
* Evid√™ncias e causalidade
   - Para H.

---

### Chunk 18/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** results | **Similarity:** 0.581

e plasma sodium levels in patients with the syndrome of inappropriate anti-diuresis. J Am Soc Nephrol. 2020;31:615¬ñ24. 
32. Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Mon-nerat S, Bathelt C, Vogt DR, Berres M, Winzeler B, Bridenbaugh SA, Christ-Crain M. Treatment eÔ¨Äect of the SGLT2 inhibitor empagliÔ¨Çozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crosso-ver trial. J Am Soc Nephrol. 2023;34:322¬ñ32. 
33. Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, Hare MJL, Calder GL, Epa DS, George EM, Giri R, Kotowicz MA, Kyi M, Lafontaine N, MacIsaac RJ, Nolan BJ, O¬íNeal DN, Renouf D, Varadarajan S, Wong J, Xu S, Bach LA. SGLT2 inhibi-tors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019;104:3077¬ñ87. 
34. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czer-wiec FS, Orlandi C, SALT Investigators.

---

### Chunk 19/30
**Article:** Dieta Cetog√™nica - Parte I (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.579

sa magra.
**Operacionaliza√ß√£o e fisiologia: hidrata√ß√£o, eletr√≥litos, glicose, glicog√™nio e m√©tricas (GKI) reduzem sintomas iniciais e orientam terapia.**
- Fase inicial: mobiliza√ß√£o de ~500 g de glicog√™nio (100 g f√≠gado, 400 g m√∫sculo) libera ~1 kg de √°gua (2 g √°gua por 1 g glicog√™nio), explicando ‚Äúperda de √°gua‚Äù na primeira semana.
- Hidrata√ß√£o/eletr√≥litos: ~2 litros de l√≠quidos/dia; 1 colher de ch√° de sal seguida de √°gua melhora sintomas em ~15 minutos; considerar sensibilidade ao sal (10%‚Äì20% dos hipertensos podem piorar).
- Glicemia: dieta normal 80‚Äì120 mg/dL; cetog√™nica 65‚Äì80 mg/dL; jejum em gestantes ~60 mg/dL; <70 mg/dL pode ser perigoso com insulina; extremos incluem 600 mg/dL em DT1 sem insulina e >300 mg/dL na cetoacidose; em jejum prolongado, 30 mg/dL pode ser tolerado quando h√° cetonas.

---

### Chunk 20/30
**Article:** Bioqu√≠mica Metab√≥lica nos Exerc√≠cios - Parte III (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.578

ol√≠ticos (como HIIT) ao diminuir a acidose. No entanto, para emagrecimento, onde a acidose √© desej√°vel para estimular o GH, seu uso pode ser contraproducente.
## Conte√∫do Remanescente
1. Detalhes sobre suplementa√ß√µes espec√≠ficas e sugest√µes de f√≥rmulas.
2. Explica√ß√£o aprofundada sobre a avalia√ß√£o bioqu√≠mica via metabol√¥mica (ex: medi√ß√£o de am√¥nia, oxaloacetato).
3. Discuss√£o sobre o sistema glicol√≠tico l√°tico e marcadores como LDH.
4. Detalhes sobre o metabolismo da carnosina e a raz√£o para altera√ß√µes de TSH/T3 em d√©ficit energ√©tico.
5. Explica√ß√£o do porqu√™ uma pessoa com padr√£o de burnout tem dificuldade para dormir.

---

## Meeting Highlights

### Diagn√≥stico Metab√≥lico Individualizado
A resposta ao exerc√≠cio √© √∫nica para cada indiv√≠duo, exigindo uma an√°lise bioqu√≠mica para prescrever a "dose" correta de treino e nutri√ß√£o.
- A resposta hormonal e metab√≥lica ao exerc√≠cio varia drasticamente, tornando a avalia√ß√£o individual essencial.

---

### Chunk 21/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.577

neinglomerularltration,particularlyamongpeoplewithalowGFR.3.9Glucagon-likepeptide-1receptoragonists(GLP-1RA)TheWorkGrouphighlightsakeyrecommendationandpracticepointfromtheKDIGO2022ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease.23Recommendation3.9.1:InadultswithT2DandCKDwhohavenotachievedindividualizedglycemictargetsdespiteuseofmetforminandSGLT2inhibitortreatment,orwhoareunabletousethosemedications,werecommendalong-actingGLP-1RA(1B).PracticePoint3.9.1:ThechoiceofGLP-1RAshouldprioritizeagentswithdocumentedcardiovascularbenets.3.10MetabolicacidosisPracticePoint3.10.1:InpeoplewithCKD,consideruseofpharmacologicaltreatmentwithorwithoutdietaryinterventiontopreventdevelopmentofacidosiswithpotentialclinicalimplications(e.g.,serumbicarbonate<18mmol/linadults).PracticePoint3.10.2:MonitortreatmentformetabolicacidosistoensureitdoesnotresultinserumbicarbonateconcentrationsexceedingtheupperlimitofnormalanddoesnotadverselyaffectBPcontrol,serumpotassium,oruidstatus.3.11Hyperkal

---

### Chunk 22/30
**Article:** Bioqu√≠mica Metab√≥lica nos Exerc√≠cios - Parte III (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.576

do-hipotireoidismo).
- Hipertrofia invi√°vel sob catabolismo salvo interven√ß√µes hormonais n√£o-mTOR com resultados limitados.
### 15. Ferramentas de controle: limiares, zonas e FIT
- Avaliar no esporte real; definir limiar via lactato e prescrever supra-limiar (acidose controlada) ou FatMax (entre 1¬∫ e 2¬∫ limiar) para mobiliza√ß√£o de gordura sem excessiva acidose.
- Framework FIT: frequ√™ncia, intensidade, tipo e tempo; monitorar FC, estado √°cido-base, marcadores de dano muscular, fontes energ√©ticas e risco de overtraining.
### 16. Estrat√©gia cl√≠nica integrativa e acompanhamento
- Basear-se na hist√≥ria cl√≠nica, nutri√ß√£o, bioqu√≠mica/metabolismo, estilo de vida, equil√≠brio hormonal.
- Iniciar com exames simples (sangue, bioimped√¢ncia), aplicar interven√ß√µes personalizadas e reavaliar em 1‚Äì2 meses, mantendo ciclo de melhoria cont√≠nua.
## ‚ùì Perguntas
- [Inserir Pergunta/Confus√£o]
## üìö Tarefas/Assignments
- [ ] 1.

---

### Chunk 23/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.576

s206‚Äì217,Copyright¬™2018,withpermissionfromtheNationalKidneyFoundation,Inc.541
00.20.40.60.81Density2.533.544.555.566.5Potassium, mmol/
eGFR 60+eGFR 30‚Äì59eGFR <30
Figure29|Distributionofbloodpotassiumingeneralpopulationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium,byestimatedglomerularltrationrate(eGFR).Densityreferstotheproportionofthepopulationexperiencing
serumpotassiumlevel(e.g.,0.08ofthepopulationwithaGFR>60haveapotassiumof3.8;conversely,0.2ofthepopulationwitha
GFR<30haveapotassiumof5.5).ReproducedfromKovesdyCP,MatsushitaK,SangY,etal.Serumpotassiumandadverseoutcomes
acrosstherangeofkidneyfunction:aCKDPrognosisConsortium
meta-analysis.EuropeanHeartJournal2018;39:1535‚Äì1542bypermissionofOxfordUniversityPressonbehalfoftheEuropean
SocietyofCardiology.555Allrightsreserved.¬™TheAuthor(s)2018.InclusionunderaCreativeCommonslicenseisprohibited.https://doi.org/10.1093/eurheartj/ehy100
chapter3www.kidney-international.orgS224KidneyInternational(2024)105(Suppl4S),S11

---

### Chunk 24/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.572

iskofdisease
progression.395,552Itshouldalsobenotedthatforyoungerchildren,thenormalrangeforsodiumbicarbonateisaslow
as17mmol/l.Inchildren,metabolicacidosisisalsolikelyto
causegrowthretardation.DatafromtheobservationalCKiDstudyrevealedthatprepubertalchildrenwithacidosiswhoweretreatedwithalkalihadimprovedgrowth.553InchildrenwithnormalGFRbutrenaltubularacidosis,prolonged
acidosiscanalsoresultinpoorgrowth.TheKDOQI
guidelineonbonemetabolismforchildrenwithCKD
recommendsthepreventionofacidosisinchildrento
optimizegrowth.554TherehavenotbeenanytrialsexaminingtheeffectofbicarbonatesupplementationonCKDprogressionorgrowthinchildren.3.11HyperkalemiainCKDDenitionandprevalence.Potassiumiskeytocellmem-braneelectrophysiology,withabnormalitiespredisposingtoabnormalcardiacconductionandarrhythmias.Thekidneys
playakeyroleinpotassiumhomeostasiswithdecreasedGFR
generallyassociatedwithincreasedpotassiumconcentration
(Table24;Figure29555).Thedenitionofhyperkalemiaisbasedonthedistributionofpotassiumvaluesinth

---

### Chunk 25/30
**Article:** Serum sodium within the normal range and its U-shaped relationship with biological aging in U.S. adults (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.572

. (2020) 225:117¬ñ23. doi: 
10.1016/j.jpeds.2020.04.048
 23. Ostrominski JW, Mha SVA, Javedbutler M, Fonarow GC, Hirsch JS, Ms SRP, et al. 
Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 
1999-2020. 
JAMA Cardiology
. (2023) 8:1050. doi: 
10.1001/jamacardio.2023.3241
 24. Katz M. Hyperglycemia-induced hyponatremia ¬ó calculation of expected serum 
sodium depression. 
N Engl J Med
. (1973) 289:843¬ñ4. doi: 
10.1056/NEJM197310182891607
 25. Stookey JD, Barclay D, Arie A, Popkin BM. e altered uid distribution in obesity 
may reect plasma hypertonicity. 
Eur J Clin Nutr
. (2007) 61:190¬ñ9. doi: 
10.1038/sj.ejcn.1602521
 26. Klemera P, Doubal S. A new approach to the concept and computation of 
biological age. 
Mech Ageing Dev
. (2006) 127:240¬ñ8. doi: 
10.1016/j.mad.2005.10.004
 27. Oh SW, Baek SH, An JN, Goo HS, Kim S, Na KY, et al. Small increases in plasma 
sodium are associated with higher risk of mortality in a healthy population.

---

### Chunk 26/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.572

reserved.¬™TheAuthor(s)2018.InclusionunderaCreativeCommonslicenseisprohibited.https://doi.org/10.1093/eurheartj/ehy100
chapter3www.kidney-international.orgS224KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314

Table25|Factorsandmechanismsthatimpactonpotassiummeasurements556,569-575Factor/mechanismPossiblecause/clinicalimplicationPseudohyperkalemia‚ÄîinvivoserumpotassiumisnormalandcommonlyGFRpreserved,butduringtheprocessofdrawingbloodorclotting,therehasbeenareleaseof
intracellularpotassiumTighttourniquetHand/armexercisingorclenchingatthetimeofblooddrawHemolysisduetovigorousshakingofbloodvial/inappropriateblooddrawequipment/inappropriatestorageofsamplesIfsuspected,bloodshouldberetakenandanalyzedintheappropriatemannerandtimeframe556,569Presenceofthrombocytosis/leukocytosisIfsuspected,takeplasmapotassiumasserumpotassiummaybefalselyincreased570HyperkalemiaduetodisruptioninthemechanismofshiftingpotassiumoutofcellsIncreaseinplasmaosmolarity(e.g.,dehydrationandhyperglycemia)Massivetiss

---

### Chunk 27/30
**Article:** Urea levels and cardiovascular disease in patients with chronic kidney disease (2022)
**Journal:** Nephrology Dialysis Transplantation
**Section:** other | **Similarity:** 0.571

20.3(5.1)0%Ageatbaseline(years)69[61‚Äì77]68[60‚Äì76]69[61‚Äì77]69[61‚Äì77]0.130%Men,n(%)666566670.710Smoking,n(%)0.030.8Never-smoker,n(%)40.644.539.637.7Currentsmoker,n(%)12.611.711.814.4Formersmoker,n(%)46.843.848.547.9eGFRatbaseline(mL/min/1.73m)33.5(11.6)43.5(9.9)32.6(8.9)24.5(7.0)<0.0010%Albumin-orprotein-to-creatinineratio<0.0018.0A1(normaltomildlyincreased),n(%)28.642.127.016.9A2(moderatelyincreased),n(%)31.831.833.729.7A3(severelyincreased),n(%)39.626.139.253.4Bodymassindex(kg/m)28.8(5.8)28.3(5.2)28.7(5.9)29.5(6.3)<0.0012.0%Diabetes,n(%)44.836.843.953.6<0.0010.2Systolicbloodpressure(mmHg)142(20)142(20)142(21)143(20)0.322.3%Historyofcardiovasculardisease,n(%)53.947.354.659.6<0.0011.3Anaemia,n(%)38.321.135.857.8<0.0010.3Serumbicarbonate(mmol/L)25.0(3.4)25.8(3.1)24.9(3.3)24.1(3.6)<0.0016.9%Serumalbumin(g/L)40.4(4.5)40.6(4.4)40.5(4.2)39.9(4.9)0.00915.2%High-sensitivityC-reactiveprotein(mg/L)2.5[1.1‚Äì5.9]2.2[1.1‚Äì5.0]2.5[1.1‚Äì5.4]2.9[1.2‚Äì7.1]<0.00117.6%Historyofacutekidneyinj

---

### Chunk 28/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.569

cid-richfoodsand/orincreasetheintakeof
alkaline-richfoodsreducethenetendogenousacidproduction
andcanserveasanadditionalstrategytocontrolmetabolic
acidosisinpeoplewithCKD.546,547Suchdietsaregenerallylowinanimalproteinorhaveahigherconsumptionofplant-based
foodsoveranimal-basedfoods(i.e.,plant-dominantdietssuch
asMediterraneanorvegetariandiets).FoursmallRCTsofalkaline-richplant-baseddietsinadultswithCKD
demonstrateacomparablebenettooralsodiumbicarbonateincontrollingmetabolicacidosis.548‚Äì551SpecialconsiderationsPediatricconsiderations.Asinadults,childrenwithCKDoftenhavemetabolicacidosis.IntheCKiDandtheCardio-vascularComorbidityinChildrenwithChronicKidneyDiseaseStudy(4C)studies,38%‚Äì60%ofchildrenhadaserumbicar-bonateof<22mmol/l,varyingbyCKDcategory.Lowbicar-bonatewasassociatedwithincreasedriskofdisease
progression.395,552Itshouldalsobenotedthatforyoungerchildren,thenormalrangeforsodiumbicarbonateisaslow
as17mmol/l.Inchildren,metabolicacidosisisalsolikelyto
causegrowthretardation.Datafro

---

### Chunk 29/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.569

aticreviews,asavailable.DetailsofthePICOSforthesequestionsarealsoprovidedinTable44.Literaturesearchesandarticleselection.SearchesforRCTswereconductedonPubMed,Embase,andtheCochrane
CentralRegisterofControlledTrials(CENTRAL),and
searchesfordiagnosis/prognosisstudieswereconductedon
PubMed,Embase,andCINAHL.Fortopicswithavailable
existingreviews,thereviewwasusedandanupdatedsearchwasconducted.ThesearchstrategiesareprovidedinAppendixA:SupplementaryTableS1.Toimproveefciencyandaccuracyinthetitle/abstractscreeningprocessandtomanagetheprocess,searchresults
wereuploadedtoaweb-basedscreeningtool,PICOPortal
(www.picoportal.net).PICOPortalusesmachinelearningtosortandpresentthosecitationsmostlikelytobepromotedto
full-textscreeningrst.Thetitlesandabstractsresultingfrom
methodsforguidelinedevelopmentwww.kidney-international.orgS274KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314

Table44|ClinicalquestionsandsystematicreviewtopicsinPICOSformatChapter1Evaluationofchronickidneydisease(CKD)Clinicalquesti

---

### Chunk 30/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.569

versusplaceboonannualrateofchangeinestimatedglomerularltrationrate(GFR)bykeysubgroupsintheStudyofHeartandKidneyProtectionWithEmpagliozin(EMPA-KIDNEY)S220Figure26.Serumpotassiummonitoringduringtreatmentwithanonsteroidalmineralocorticoidreceptorantagonist(MRA)(nerenone)S221Figure27.EffectofnerenoneversusplaceboonkidneyandcardiovascularoutcomesinpooledanalysesfromtheFinerenoneinReducingKidneyFailureandDiseaseProgressioninDiabeticKidneyDisease(FIDELIO-DKD)andFinerenoneinReducingCardiovascularMortalityandMorbidityinDiabeticKidneyDisease
(FIGARO-DKDtrials)S222Figure28.Associationbetweenestimatedglomerularltrationrate(eGFR)withserumbicarbonateconcentrationingeneralpopulationandhigh-riskcohortsfromtheChronicKidneyDisease
PrognosisConsortium,bylevelofalbuminuria(A1‚ÄìA3)S224Figure29.Distributionofbloodpotassiumingeneralpopulationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium,byestimatedglomerularltrationrate(eGFR)S224Figure30.Meta-analyzedadjustedprevalenceofhyperkalemi

---

